Medical Device Skin Irritation Testing: Standards, Methods and Regulatory Requirements

Medical device skin irritation testing is a core element of the biological safety evaluation required under the ISO 10993 series of standards and by regulatory authorities worldwide, including the NMPA, US FDA, and notified bodies under the EU MDR. This testing determines whether a device or its leachable extracts can induce localized, reversible inflammatory reactions such as erythema and edema at skin, mucosal, or compromised-surface contact sites. This article explains the applicable standards, sample categories, test items, methodologies, acceptance criteria, and typical regulatory applications of skin irritation testing for medical devices.

Technical Overview

Medical device skin irritation testing is performed to determine whether a device, or chemical substances leaching from it, can provoke a localized, non-immunological inflammatory response in living tissue at the site of contact. Irritation typically manifests as erythema (redness) and edema (swelling), and it is mechanistically distinct from sensitization, which is an immune-mediated delayed hypersensitivity reaction evaluated under separate protocols.

The evaluation is conducted within the risk management framework of ISO 10993-1 (Biological evaluation of medical devices, Part 1: Evaluation and testing within a risk management process). Specific test methodologies for irritation are defined in ISO 10993-10 (Tests for irritation and skin sensitization) and ISO 10993-23 (Tests for irritation), while sample preparation and extraction are governed by ISO 10993-12. In China, the corresponding national standards, GB/T 16886.1, GB/T 16886.10, GB/T 16886.23, and GB/T 16886.12, are technically aligned with their ISO counterparts and are referenced by regulators in medical device registration guidance.

Under the ISO 10993-1 categorization scheme, irritation testing is indicated for surface-contacting devices (intact skin, mucosal membranes, breached or compromised surfaces), external communicating devices (indirect blood contact, tissue, bone, and dentinal contact), and implantable devices. The nature, duration, and frequency of patient contact determine the extent of testing required. A weight-of-evidence approach combining material characterization, extractables and leachables data, and toxicological risk assessment may justify omitting specific tests; however, irritation data are customarily expected for any device with skin or mucosal contact, and accredited third-party laboratories routinely include these endpoints in biocompatibility test plans.

Testing Samples

Surface-Contacting Medical Devices

These devices contact intact skin, mucosal membranes, or breached and compromised surfaces. Typical samples include adhesive bandages, wound dressings, transparent film dressings, hydrocolloids, electrode pads and conductive gels, fixation tapes, compression bandages and garments, examination and surgical gloves, respiratory masks and headgear, ostomy appliances and skin barriers, external prosthetic components, and transdermal delivery system components. For these products, dermal or mucosal irritation models are selected according to the actual contact tissue.

External Communicating Medical Devices

These devices contact tissue, bone, dentin, or blood pathways at natural or surgical openings. Representative samples include infusion sets, intravenous catheters, syringes and stopcocks, blood administration tubing, extracorporeal circulation circuits, hemodialyzers, endotracheal tubes, urinary catheters, gastroenteral feeding tubes, and laparoscopic instrument components that contact internal tissue. Extract-based intracutaneous reactivity testing is the standard approach for this category.

Implantable Medical Devices

Although implants do not contact the skin during clinical use, their extracts are evaluated for localized tissue irritation potential because leachable substances can provoke inflammatory responses at the implantation site. Samples in this category include orthopedic implants and fixation hardware, vascular stents and grafts, pacemaker leads and encapsulations, sutures, staples, and absorbable scaffolds. Intracutaneous reactivity of polar and non-polar extracts is the recognized screening endpoint.

Materials, Components, and Extracts

Testing can also be performed on upstream or support materials, including raw polymers and cured elastomers, adhesives, coatings, colorants and additives, primary packaging that contacts the device, and process-contact materials. Samples may be submitted as finished, sterilized devices, as representative coupons of the final material formulation, or as extracts prepared in polar media such as 0.9 percent sodium chloride solution and non-polar media such as sesame or cottonseed oil, with additional solvents justified by the chemical composition of the device.

Testing Items

The irritation evaluation battery is selected based on the tissue contacted and the duration of contact, and commonly includes the following items:

• Intracutaneous (intradermal) reactivity testing using device extracts in the rabbit model
• Acute dermal irritation testing with single exposure in the rabbit model
• Dermal irritation testing with repeated or cumulative exposure for prolonged-contact devices
• Oral, vaginal, rectal, and penile mucosal irritation testing for devices contacting these membranes
• Ocular irritation testing for devices with eye contact, such as contact lens care products and ophthalmic instruments
• In vitro skin irritation testing using reconstructed human epidermis (RhE) tissue models as an animal-free alternative

The endpoints recorded across these tests include erythema and eschar formation, edema, and, for mucosal and ocular studies, additional observations such as discharge, ulceration, and tissue integrity changes.

Testing Methods

Sample Preparation and Extraction (ISO 10993-12)

Test articles are prepared under aseptic conditions using standardized surface-area-to-volume or mass-to-volume ratios, commonly 3 cm²/mL or 6 cm²/mL depending on sample thickness, or 0.1 to 0.2 g/mL for irregular or absorbent materials. Both a polar solvent (0.9 percent sodium chloride injection) and a non-polar solvent (sesame or cottonseed oil) are typically used unless chemical characterization justifies otherwise. Extraction is performed at one of the standard condition sets, such as 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, selected so that the temperature does not exceed the thermal limits of the material. Blank control media are extracted in parallel under identical conditions to serve as comparators.

Intracutaneous Reactivity Test (Rabbit Model)

Healthy adult albino rabbits are used. A 0.2 mL aliquot of each test extract is injected intradermally at five sites on one side of the dorsal midline, while the corresponding blank extraction medium is injected at five matched sites on the contralateral side. Injection sites are observed and scored for erythema and edema on a 0 to 4 scale at approximately 24, 48, and 72 hours after injection. The test is considered acceptable when the difference between the mean scores of the test extract sites and the blank control sites does not exceed 1.0, indicating no significant irritant potential.

Acute Dermal Irritation Test (Rabbit Model)

The dorsal area of the rabbit is clipped free of fur, and gauze patches of approximately 2.5 cm by 2.5 cm are saturated with about 0.5 mL of test extract or blank control and applied to the skin under semi-occlusive or occlusive dressings. Exposure duration reflects the intended clinical contact, with a minimum of 4 hours and up to 23 ± 2 hours for prolonged-contact devices. Scoring for erythema and edema is performed at patch removal and at approximately 24, 48, and 72 hours thereafter. The Primary Irritation Index (PII) is calculated as the sum of all scores divided by the total number of scored sites, and results are classified as negligible (0.0 to 0.4), slight (0.5 to 1.9), moderate (2.0 to 4.9), or severe (5.0 to 8.0) irritation.

Mucosal and Ocular Irritation Tests

Route-specific protocols are applied when devices contact mucosal membranes. Extracts are instilled into or applied directly to the oral, vaginal, rectal, or penile mucosa of suitable animal models, using either single-dose screening designs or repeated-dose designs of up to 14 days for devices with extended or repeated contact. Ocular irritation is evaluated by applying the test article or extract to the conjunctival sac or by controlled contact methods, followed by standardized scoring of the cornea, iris, and conjunctiva. These studies require concurrent negative and positive controls to demonstrate model sensitivity.

In Vitro Skin Irritation (Reconstructed Human Epidermis)

ISO 10993-23 establishes in vitro test methods using reconstructed human epidermis (RhE) tissue models, consistent with the principles of OECD Test Guideline 439. Test extracts or solid materials are applied topically to the stratum corneum surface of the three-dimensional tissue constructs. After a defined exposure and recovery period, tissue viability is quantified using the MTT metabolic conversion assay. Viability at or below 50 percent of the negative control value classifies the sample as an irritant. This approach substantially reduces animal use and is increasingly recognized by regulatory authorities; however, its applicability must be verified for the specific device category, chemical class, and target market, since MTT-interfering substances and certain material types may require correction procedures or in vivo confirmation.

Scoring, Interpretation, and Reporting

All studies follow the Draize-type ordinal scoring scales for erythema and eschar (0 to 4) and edema (0 to 4), assessed by trained observers under controlled lighting. Final reports document the test article description, extraction conditions, animal or tissue model justification, individual and mean scores, comparison against blank controls, and the biological safety conclusion. Statistical or severity-based interpretation is then integrated into the overall ISO 10993-1 biological evaluation report.

Applications

Skin irritation testing data support product development and market access across the full medical device lifecycle. Principal applications include:

• Registration submissions to national regulatory authorities, including NMPA device registration dossiers, US FDA 510(k), De Novo, and PMA submissions, and EU MDR technical documentation for CE marking
• Completion of the ISO 10993-1 biological evaluation test matrix required for surface-contacting, external communicating, and implantable device categories
• Evaluation of design and process changes, such as new materials, adhesives, or coatings, changes in sterilization method or parameters, residual ethylene oxide assessment, and packaging modifications
• Supplier qualification and incoming material control programs within quality management systems
• Research and development screening of candidate materials prior to committing to in vivo programs
• Post-market surveillance, complaint investigation, and re-evaluation triggered by adverse event reports

FAQ

Which medical devices require skin irritation testing?

Any device that contacts intact skin, mucosal membranes, or breached or compromised surfaces, as well as external communicating and implantable devices, generally requires irritation evaluation. The specific endpoint, such as dermal, mucosal, ocular, or intracutaneous reactivity, is selected based on the contact tissue and the duration and frequency of contact defined in the intended use.

What is the difference between ISO 10993-10 and ISO 10993-23?

ISO 10993-10 covers tests for both irritation and skin sensitization, while ISO 10993-23 specifically addresses irritation test methods, including validated in vitro reconstructed human epidermis alternatives and refined in vivo procedures. Many test plans cite both parts together, with ISO 10993-23 serving as the current methodological reference for irritation endpoints.

Can in vitro tests replace rabbit studies?

For many surface-contacting devices, in vitro RhE testing in accordance with ISO 10993-23 can replace the rabbit dermal irritation test and, in defined cases, provide supporting evidence for other routes. Acceptance varies by jurisdiction and device category, so sponsors should confirm the regulatory status of in vitro data with the target market authority or consult accredited third-party laboratories when constructing the test plan.

What result constitutes a pass?

In the intracutaneous reactivity test, a passing result is a difference of no more than 1.0 between the mean erythema and edema scores of the test extract sites and the blank control sites. In dermal irritation studies, a Primary Irritation Index in the negligible or slight range, consistent with the device's risk profile, is typically acceptable. In the in vitro RhE test, tissue viability above 50 percent of the negative control indicates the sample is not classified as an irritant.

How much sample is needed and what is the typical turnaround time?

Sample requirements depend on the surface area or mass needed to meet the extraction ratios for both polar and non-polar solvents, often corresponding to several finished devices or a defined area of material. In vivo intracutaneous and dermal studies are generally completed within two to four weeks after sample conditioning and extraction, while in vitro RhE studies can often be completed within one to two weeks.

Which extraction conditions should be selected?

The extraction condition is chosen to maximize leachable release without degrading or transforming the material. Commonly used conditions include 37°C for 72 hours for heat-sensitive materials, 50°C for 72 hours or 70°C for 24 hours for moderate thermal stability, and 121°C for 1 hour for materials that withstand autoclave temperatures. Justification for the selected condition should be documented in the test report.

Is irritation testing required for single-use devices that contact intact skin only briefly?

Even limited-duration contact devices, such as electrode pads or adhesive accessories, are normally expected to have irritation data, although a documented chemical characterization and toxicological risk assessment may sometimes justify a reduced testing scope. The final decision should be documented within the biological evaluation plan aligned with ISO 10993-1.